Cerenis Raises Series B

Cerenis Therapeutics SA, a France-based drug company focused on cardiovascular and metabolic diseases, has raised Euro 42.1 million in Series B funding. TVM Capital led the deal, and was joined by OrbiMed Advisors and return backers Sofinnova Partners, HealthCap, Alta Partners, EDF Ventures and NIF SMBC Ventures. www.cerenis.com